Long-Term Outcomes in HIV(+) Kidney Re-Tranpslant (ReTx) Recipients vs. Primary Transplant (PrimTx) Recipients.
Drexel University College of Medicine, Philadelphia
Meeting: 2017 American Transplant Congress
Abstract number: D120
Keywords: HIV virus, Kidney transplantation, Outcome, Retransplantation
Session Information
Session Name: Poster Session D: Kidney: Acute Cellular Rejection
Session Type: Poster Session
Date: Tuesday, May 2, 2017
Session Time: 6:00pm-7:00pm
Presentation Time: 6:00pm-7:00pm
Location: Hall D1
Hahnemann University Hospital has performed 113 kidney transplants, including 7 ReTx. Herein we describe characteristics and allograft outcomes of HIV(+) kidney transplant recipients based on ReTx status.
Methods: We compared recipient, donor, allograft characteristics between ReTx(n=7) and PrimTx(n=106) HIV(+) kidney recipients at a single center. Immunosuppression consisted of antibody induction (basiliximab (n=112), antithymocyte globulin (n=1,ReTx), and concomitant IVIG (n=19, 2 ReTx/17 CRD)), calcineurin-inhibitor, antiproliferatives, and prednisone. Rejections and allograft outcomes were analyzed between the two cohorts.
Results: Patient characteristics were similar, except more female ReTx (Table 1).Rejection rates were increased in the ReTx cohort (figure 1), which likely impacted survival. Kaplan-Meier curve for allograft survival is shown in figure 2.
Conclusion: Both PrimTx and ReTx HIV(+) kidney recipients are at high risk for rejection and allograft failure. Future studies may focus on the ideal immunosuppression required to improve outcomes for HIV(+) ReTx recipients.
| ReTx(n=7) | PrimTx(n=106) | p-value | |
| Recipient Age (years) | 47±7 | 48±0 | 0.81 |
| Male | 57% | 88% | 0.03 |
| African American | 100% | 80% | 0.72 |
| Protease Inhibitor based ART | 71% | 51% | 0.29 |
| HCV(+) | 71% | 38% | 0.08 |
| Pre-transplant PRA | 30±43% | 3±10% | 0.44 |
| Deceased Donor | 100% | 89% | 0.40 |
| Donation after Cardiac Death | 14% | 10% | 0.75 |
| KDRI | 1.412±0.69 | 1.318±0.48 | 0.83 |
| HLA mismatch | 4.1±1.1 | 4.2±1.6 | 0.57 |
| Delayed Graft Function | 57% | 57% | 0.98 |
CITATION INFORMATION: Malat G, Guy S, Ranganna K, Reich D, Xiao G, Talluri S, Harhay M, Levin Mizrahi L, Culkin C. Long-Term Outcomes in HIV(+) Kidney Re-Tranpslant (ReTx) Recipients vs. Primary Transplant (PrimTx) Recipients. Am J Transplant. 2017;17 (suppl 3).
To cite this abstract in AMA style:
Malat G, Guy S, Ranganna K, Reich D, Xiao G, Talluri S, Harhay M, Mizrahi LLevin, Culkin C. Long-Term Outcomes in HIV(+) Kidney Re-Tranpslant (ReTx) Recipients vs. Primary Transplant (PrimTx) Recipients. [abstract]. Am J Transplant. 2017; 17 (suppl 3). https://atcmeetingabstracts.com/abstract/long-term-outcomes-in-hiv-kidney-re-tranpslant-retx-recipients-vs-primary-transplant-primtx-recipients/. Accessed November 22, 2024.« Back to 2017 American Transplant Congress